Q-omics provides the consensus-scored TAB3 profile across patient tissues and cancer cell-line models. TAB3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TAB3 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, TAB3 RNA expression shows 20,826 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BLCA, and THYM as cancer lineages where TAB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAB3 survival associations across molecular data types. TAB3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAB3 RNA expression–survival associations across cancer types. High TAB3 expression shows unfavorable associations in LIHC, BLCA and LGG, but favorable associations in KIRC, SCLC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for TAB3 RNA expression.
This table summarizes TAB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TAB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAB3 shows lower tumor expression in THCA, UCEC and KIRC and higher tumor expression in BLCA, LIHC and BRCA. The BLCA box plot shows higher TAB3 RNA expression in tumor versus normal tissue (log2 FC = +0.572, t-test p < 0.001).
This table shows molecular features associated with TAB3 in patient tissues and cancer cell lines. In patient samples, TAB3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
